Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
PURPOSE Eicosapentaenoic acid ( EPA ) has been proposed to have specific anticachectic effects . This trial compared EPA diethyl ester with placebo in cachectic cancer patients for effects on weight and lean body mass . PATIENTS AND METHODS Five hundred eighteen weight-losing patients with advanced gastrointestinal or lung cancer were studied in a multicenter , double-blind , placebo controlled trial . Patients were r and omly assigned to receive a novel preparation of pure EPA at a dose of 2 g or 4 g daily or placebo ( 2 g EPA , n = 175 ; 4 g EPA , n = 172 ; placebo , n = 171 ) . Patients were assessed at 4 weeks and 8 weeks . RESULTS The groups were well balanced at baseline . Mean weight loss at baseline was 18 % ( n = 518 ) . Over the 8-week treatment period , both intention-to-treat analysis and per protocol analysis revealed no statistically significant improvements in survival , weight , or other nutritional variables . There was , however , a trend in favor of EPA with analysis of the primary end point , weight , at 8 weeks showing a borderline , nonsignificant treatment effect ( P = .066 ) . Relative to placebo , mean weight increased by 1.2 kg with 2 g EPA ( 95 % CI , 0 kg to 2.3 kg ) and by 0.3 kg with 4 g EPA ( -0.9 kg to 1.5 kg ) . CONCLUSION The results indicate no statistically significant benefit from single agent EPA in the treatment of cancer cachexia . Future studies should concentrate on other agents or combination regimens
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .